Delivering the 2.4 Percent: Unlocking UK Pharma R&D Investment through Evidence-Based Policies

Simon Brassel;Graham Cookson

Contract Research from Office of Health Economics

Abstract: In the 2017 Industrial Strategy, the Government committed to increasing investment in UK Research and Development to the OECD-average of 2.4% of Gross Domestic Product (GDP) by 2027, with a longer-term goal of reaching 3% to put the UK in the upper quartile. Whilst there is universal agreement that increasing R&D investment in the UK is a worthy goal, there is an ongoing discussion over how best to achieve it. To stimulate this debate, the Office of Health Economics (OHE) was commissioned to investigate how the UK Government and the UK pharmaceutical industry can collaborate to deliver the life science sector’s share of this ambitious R&D target. The report finds that the pharmaceutical industry will be a key partner in realising the Government’s ambition and based upon evidence from a range of similar countries identifies the most appropriate policies to delivering the 2.4% goal.

Keywords: Delivering; the; 2.4; Percent:; Unlocking; UK; Pharma; R&D; Investment; through; Evidence-Based; Policies (search for similar items in EconPapers)
JEL-codes: I1 (search for similar items in EconPapers)
Date: 2020-06-01
References: Add references at CitEc
Citations: View citations in EconPapers (1)

Downloads: (external link)
https://www.ohe.org/publications/delivering-24-per ... ookson-delivering-2/ (application/pdf)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:ohe:conres:002277

Access Statistics for this paper

More papers in Contract Research from Office of Health Economics Contact information at EDIRC.
Bibliographic data for series maintained by Publications Manager ( this e-mail address is bad, please contact ).